acetylcysteine 600mg tablets
alliance healthcare (distribution) ltd - acetylcysteine - oral tablet - 600mg
acetylcysteine 600mg capsules
tor generics ltd - acetylcysteine - oral capsule - 600mg
acetylcysteine 600mg capsules
a a h pharmaceuticals ltd - acetylcysteine - oral capsule - 600mg
acetylcysteine 600mg tablets
colorama pharmaceuticals ltd - acetylcysteine - oral tablet - 600mg
acetylcysteine 600mg capsules
alissa healthcare research ltd - acetylcysteine - oral capsule - 600mg
acetylcysteine 600mg tablets
alissa healthcare research ltd - acetylcysteine - oral tablet - 600mg
acetylcysteine 600mg capsules
alliance healthcare (distribution) ltd - acetylcysteine - oral capsule - 600mg
acetaminophen injection solution
avir pharma inc. - acetaminophen - solution - 10mg - acetaminophen 10mg - miscellaneous analgesics and antipyretics
tri-mag supreme powder
designs for health pty ltd - acetyl levocarnitine hydrochloride,glutamine,levomefolate glucosamine,magnesium amino acid chelate,magnesium glycerophosphate,magnesium orotate,mecobalamin (co-methylcobalamin),nicotinamide,pyridoxal 5-phosphate,riboflavin sodium phosphate,taurine,thiamine hydrochloride -
acetylcysteine injection, solution
sagent pharmaceuticals - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and miscarriage